The role of osteoprotegerin in cardiovascular disease - PubMed (original) (raw)
Review
The role of osteoprotegerin in cardiovascular disease
Martina Montagnana et al. Ann Med. 2013 May.
Free article
Abstract
Osteoprotegerin (OPG) is a 401 amino acid N-glycosylated protein, which is highly expressed in a large number of tissues. OPG mainly binds to two ligands, i.e. RANKL (receptor activator of nuclear factor κB ligand) and TRAIL (tumor necrosis factor- related apoptosis-inducing ligand). Upon binding to the former ligand, OPG inhibits the activation of osteoclasts and promotes apoptosis of osteoclasts, whereas the binding of OPG with TRAIL prevents apoptosis of tumor cells. There is now emerging evidence that OPG participates in the pathogenesis of atherosclerosis and cardiovascular diseases by amplifying the adverse effects of inflammation and several traditional risk factors such as hyperlipidemia, endothelial dysfunction, diabetes mellitus, and hypertension. Some epidemiological studies also showed a positive association between OPG levels and cardiovascular morbidity and mortality. The aim of this article is to provide an overview of the main biochemical, physiological, and pathological aspects of OPG biology in cardiovascular disease.
Similar articles
- Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
Harper E, Forde H, Davenport C, Rochfort KD, Smith D, Cummins PM. Harper E, et al. Vascul Pharmacol. 2016 Jul;82:30-40. doi: 10.1016/j.vph.2016.02.003. Epub 2016 Feb 24. Vascul Pharmacol. 2016. PMID: 26924459 Review. - Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE, Holen I. Van Poznak C, et al. J Clin Pathol. 2006 Jan;59(1):56-63. doi: 10.1136/jcp.2005.026534. J Clin Pathol. 2006. PMID: 16394281 Free PMC article. - Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P. Collin-Osdoby P. Circ Res. 2004 Nov 26;95(11):1046-57. doi: 10.1161/01.RES.0000149165.99974.12. Circ Res. 2004. PMID: 15564564 Review. - Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
Sandra F, Hendarmin L, Nakamura S. Sandra F, et al. Oral Oncol. 2006 Apr;42(4):415-20. doi: 10.1016/j.oraloncology.2005.09.009. Epub 2006 Jan 18. Oral Oncol. 2006. PMID: 16413220 - Elevated serum osteoprotegerin levels in women: friend or foe?
Sasso GR, Florencio-Silva R, Simões RS, Baracat MC, Soares Júnior JM, Baracat EC. Sasso GR, et al. Rev Assoc Med Bras (1992). 2015 Nov-Dec;61(6):524-9. doi: 10.1590/1806-9282.61.06.524. Rev Assoc Med Bras (1992). 2015. PMID: 26841162 Review.
Cited by
- Vascular Cytokines and Atherosclerosis: Differential Serum Levels of TRAIL, IL-18, and OPG in Obstructive Coronary Artery Disease.
Bate KA, Genetzakis E, Vescovi J, Gray MP, Celermajer DS, McGuire HM, Grieve SM, Vernon ST, Cartland SP, Yang JY, Kavurma MM, Figtree GA. Bate KA, et al. Biomolecules. 2024 Sep 4;14(9):1119. doi: 10.3390/biom14091119. Biomolecules. 2024. PMID: 39334884 Free PMC article. - Mechanisms of damage and therapies for cardiac amyloidosis: a role for inflammation?
Bellofatto IA, Nikolaou PE, Andreadou I, Canepa M, Carbone F, Ghigo A, Heusch G, Kleinbongard P, Maack C, Podesser BK, Stamatelopoulos K, Stellos K, Vilahur G, Montecucco F, Liberale L. Bellofatto IA, et al. Clin Res Cardiol. 2024 Aug 21. doi: 10.1007/s00392-024-02522-2. Online ahead of print. Clin Res Cardiol. 2024. PMID: 39167195 Review. - Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease.
Akhtar SMM, Ali A, Fareed A, Hasan J. Akhtar SMM, et al. Health Sci Rep. 2024 Jul 22;7(7):e2253. doi: 10.1002/hsr2.2253. eCollection 2024 Jul. Health Sci Rep. 2024. PMID: 39044846 Free PMC article. - Osteoprotegerin Is Essential for the Development of Endothelial Dysfunction Induced by Angiotensin II in Mice.
Dutka M, Garczorz W, Kosowska A, Buczek E, Godek P, Wojakowski W, Francuz T. Dutka M, et al. Int J Mol Sci. 2024 Jun 11;25(12):6434. doi: 10.3390/ijms25126434. Int J Mol Sci. 2024. PMID: 38928140 Free PMC article. - Serum osteoprotegerin and its gene polymorphisms in patients with Takayasu's arteritis: a bicentric cross-sectional study.
Cendon Duran CDS, de Falco Caparbo V, Santiago MB, Hounkpe BW, Pedreira ALS, de Souza Lima IV, Giardini HAM, Bonoldi VLN, Domiciano DS, Shinjo SK, Pereira RMR. Cendon Duran CDS, et al. Adv Rheumatol. 2024 May 28;64(1):43. doi: 10.1186/s42358-024-00384-w. Adv Rheumatol. 2024. PMID: 38807174